Articles
Kaufman MB. Pharmaceutical Approval Update. P&T 2019;44:108-109 (April). Prucalopride tablets (Motegrity), Rifamycin (Aemcolo) tablets, and dexamethasone ophtalmic insert (Dextenza).
Kaufman MB. Pharmaceutical Approval Update. P&T 2019;44:108-109 (March). Levodopa inhalation powder (Inbrija), Ravulizumab (Ultomiris) injection , and Revefenacin (Yupelri) inhalation solution.
Kaufman MB. Pharmaceutical Approval Update. P&T 2019;44:42-44(January/February). Amikacin liposome inhalation suspension (Arikayce), Baloxavir marboxil (Xofluza) tablets, and Omadacycline (Nuzyra) injection and tablets.
Kaufman MB. Rituximab Receives Label Update for ANCA-Associated Vasculitis.
Rheumatologist 2019;13(2). FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients link to article
Kaufman MB. Rituximab Receives Label Update for ANCA-Associated Vasculitis.
Rheumatologist 2019;13(1). FDA Update: Topical Plaque Psoriasis Treatment Approved; Dupilumab Will Received Priority FDA Review link to article
Kaufman MB. Pharmaceutical Approval Update. P&T 2018;43:734-735 (December). Approvals include: Lusutrombopag (Mulpleta) tablets, Fremenezumab-vfrm (Ajovy) injection, and Lanadelumab-flyo (Takhzyro) injection.
Kaufman MB. Rituximab Receives Label Update for ANCA-Associated Vasculitis.
Rheumatologist 2018;12(12). link to article
Kaufman MB. Pharmaceutical Approval Update. P&T 2018;43:659-661 (November). Approvals include: Tafenoquine tablets (Arakoda), Segesterone acetate/ethinyl estradiol vaginal system (Annovera), and cenegermin-bkbj ophthalmic solution 0.002% (Oxervate).
Kaufman MB. FDA Expands Safety Measures for Immediate Release Opioids. Rheumatologist 2018;12(11).
link to article
Kaufman MB. Suboxone 101: The Skinny on This Opioid-Dependence Drug Published October 23, 2018 American College of Emergency Physicians (ACEP) Now
link to article Last Accessed November 18, 2018
Kaufman MB. The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials. Rheumatologist 2018;12(10). link to article
Kaufman MB. New, More Potent Rabies Treatment Now Available Published September 25, 2018 American College of Emergency Physicians (ACEP) Now
link to article Last Accessed November 18, 2018
Kaufman MB. Pharmaceutical Approval Update. P&T 2018;43:528-530 (September). Approvals include: Baricitinib tablets (Olumiant), Plazomicin injection (Zemdri), and Cannabidiol oral solution ([CBD], Epidiolex).
Kaufman MB. Tanezumab Promising for OA Pain; Plus filgotinib Investigated for Psoriatic Arthritis. Rheumatologist 2018;12(9). link to article
Kaufman MB. Results From the Belimumab Safety Study. Rheumatologist 2018;12(8). link to article
Kaufman MB. Certolizumab Pegol Receives FDA Approval for Plaque Psoriasis Plus FDA updates Ixekizumab label to include genital-area psoriasis. Rheumatologist 2018;12(7):80.
Kaufman MB. Drug Safety: Fasinumab Evaluated in Clinical Trials Plus celecoxib may not pose increased heart attack or stroke risk & more. Rheumatologist 2018;12(6):64.
Kaufman MB. FDA to Review Abuse Deterrent Oxycodone Plus adalimumab biosimilar moves forward after legal battle & more. Rheumatologist 2018;12(5):67.
Kaufman MB. Ixekizumab Promising for AS Plus certolizumab pegol & psoriasis, heart risk with clarithromycin & more. Rheumatologist 2018;12(4):50.
Kaufman MB. Ferumoxytol Injection Receives New Indication Plus application for GP2017 moves ahead & loperamide abuse reported. Rheumatologist 2018;12(3):64.
Kaufman MB. Pharmaceutical Approval Update. P&T 2018;43:141-142 (March). Approvals include: Zoster Vaccine Recombinant, Adjuvanted (Shingrix), Angiotensin II Injection (Giapreza), and Glycopyrrolate Inhalation Solution (Lonhala Magnair).
Kaufman MB. Bimekizumab improves joint & skin symptoms in PsA Patients Plus EU approves certolizumab pegol for pregnant & nursing patients. Rheumatologist 2018;12(2):80.
Kaufman MB. Pharmaceutical Approval Update. P&T 2018;43:83-84 (February). Approvals include: Benznidazole, Vestronidase Alfa-vjbk (Mepsevii), and Hepatitis B Vaccine (recombinant) adjuvanted (Heplisav-B).
Kaufman MB. E6011 Safe & Well Tolerated in RA Patients Plus tocilizumab monotherapy may sustain low disease activity in RA patients. Rheumatologist 2018;12(1):72.
Kaufman MB. Pharmaceutical Approval Update. P&T 2018;43:22, 23, 60 (January). Approvals include: Latanoprostene Bunod Ophthalmic Solution (Vyzulta), Letermovir (Prevymis), and Benralizumab (Fasenra).
Kaufman MB. Pharmaceutical Approval Update. P&T 2017;42:562-563,580 (September). Approvals include: Kevzara (sarilumab), Ingrezza (valbenazine tosylate), and Bineura (cerliponase alpha)
Kaufman MB. Opana ER Pulled from U.S. Market Plus upadacitinib, abatacept, topical diclofenac sodium & more. Rheumatologist 2017;11(8):56.
Kaufman MB. Romosozumab's Uncertain Future Plus tocilizumab approved for GCA, NSAIDs & myocardial infarction risks & more. Rheumatologist 2017;11(7):56.
Kaufman MB. FDA Responds to NDA for baricitinib - NICE recommends secukinumab & more. Rheumatologist 2017;11(6):64.
Kaufman MB. Sirukumab Promising for RA Plus ustekinumab has longer efficacy duration than TNFIs for plaque psoriasis. Rheumatologist 2017;11(5):56.
Kaufman MB. Brodalumab approved for plaque psoriasis Plus baricitinib may exhibit better efficacy than adalimumab for RA. Rheumatologist 2017;11(4):56.
Kaufman MB. Physician’s Choice – Factors that influence first- and second-line biologic therapy in RA patients. Rheumatologist 2017;11(3):64.
Kaufman MB. Efficacy & Safety of Guselkumab plus FX006 promising for knee OA. Rheumatologist2017;11(2):60.
Kaufman MB. Pharmaceutical Approval Update. P&T 2017;42:90-91. Approvals include: Prasterone Vaginal Insert (Intrarosa), Crisaborole Ointment 2% (Eucrisa), and Tenofovir Alafenamide (Vemlidy)
Kaufman MB. Pharmaceutical Approval Update. P&T 2016;41:748-750. Approvals include: Lisinopril Oral Solution (Qbrelis), Etanercept-szzs (Erelzi), and Lumcaftor 100mg/Ivacaftor 125 mg (Orkambi)
Kaufman MB. Celecoxib & Cardiovascular Death NSAID safety under review. Rheumatologist 2016;10(12):40.
Kaufman MB. Biosimilar Updates Plus ixekizumab for PsA & more. Rheumatologist 2016;10(11):52.
Kaufman MB. Pharmaceutical Approval Update. P&T 2016;41:617-618,639. Approvals include: Ocaliva (Obeticholic Acid), Sofosbuvir 400 mg/Velpatasvir 100 mg (Epclusa), and Daclizumab (Zinbryta)
Kaufman MB. Abaloparatide Promising for Osteoporosis Plus NICE draft guidelines include secukinumab for ankylosing spondylitis & more Rheumatologist 2016;10(10):64.
Kaufman MB. Ixekizumab improves work productivity Plus vobarilizumab completes Phase 2B studies in RA. Rheumatologist 2016;10(9):64.
Kaufman MB. Infliximab Biosimilar Cross Reacts to Infliximab Antibodies Plus treat-to-target strategy promising for treating RA with bDMARDs & more Rheumatologist 2016;10(8):48.
Kaufman M, Pham T, Parameswaran L, Choy M. Prasugrel Hypersensitivity with respiratory distress and rash. Am J Health-Syst Pharm. 2016;73:1051-1057.
Kaufman MB. Pharmaceutical Approval Update. P&T 2016;41:476-478. Approvals include: Venetoclax (Venclexta), Riboflavin 5'-Phosphate in 20% Dextran Ophthalmic Solution and Riboflavin 5'-Phosphate Ophthalmic Solution (Photrexa Viscous and Photrexa), and Pimavanserin (Nuplazid)
Kaufman MB. Pharmaceutical Approval Update. P&T 2016;41:355-356. Approvals include: Obiltoxaximab Injection (Anthim), Uxekizumab (Taltz), and Reslizumab (Cinqair)
Kaufman MB. Updated Labeling Guides for Fluoroquinolones Plus FDA to review benzhydrocodone & acetaminophen combo. Rheumatologist 2016;10(7):51.
Kaufman MB. Etanercept for Pediatric Plaque Psoriasis? Plus OA knee pain treatment enters clinical trials & more. Rheumatologist 2016;10(6):48.
Kaufman MB. Infliximab Biosimilar Receives FDA Approval Plus Zirletta is promising for knee OA pain & golimumab completes phase 3 trial. Rheumatologist 2016;10(5):55.
Kaufman MB. Biosimilars Receive Positive News Plus apremilast proves effective for PsA with skin involvement. Rheumatologist 2016;10(4):60.
Kaufman MB. Opioid Investigated to Treat Acute & Chronic OA Pain Plus new RA treatment & more. Rheumatologist 2016;10(3):67.
Kaufman MB. Biosimilars Seek Regulatory Approval in the U.S. & Europe plus MTX underused in the U.S. & more. Rheumatologist 2016;10(2):80.
Kaufman MB. FDA Approves New Drugs for Pain, other drugs face hurdles. Rheumatologist 2016;10(1):59.
Kaufman MB.Tofacitinib on hold for Psoriasis Plus anti-TNFs top FDA list for adverse events & moreRheumatologist 2015;9(12):96.
Kaufman MB. Brentuximab vedotin & tofacitinib citrate Plus FDA warnings regarding MRI safety & hydroxyurea. Rheumatologist 2015;9(11):77.
Kaufman MB. FDA Issues Stronger NSAIDs Warning plus tofacitinib citrate & abaloparatide-SC updates. Rheumatologist 2015;9(10):92.
Kaufman MB. Herbal Products and the Pregnant Patient - D Benefits Outweigh the Risks? Summer 2015 Bulletin of the New York City Society of Health-systems Pharmacists Volume XXXX, Number 6:6-8.
Kaufman MB. Drug Updates from EULAR 2015 Guselkumab for RA & plaque psorasis, plus biosimilars. Rheumatologist 2015;9(9):77.
Kaufman MB. Biosimilar Battle Heats Up plus ixekizumab & varenicline updates. Rheumatologist 2015;9(6):88.
Kaufman MB. Biosimilar News plus drug approvals and study updates. Rheumatologist 2015;9(4):72.
Kaufman MB. CZP Studies and Highlight No New Safety Issues plus clazakizumab & hydrocodone bitartrate extended-release capsules. Rheumatologist 2015;9(3):73.
Kaufman MB. Potentially serious interactions for trimethoprim/sulfamethoxazole come to light plus updates on buprenorphine, diclofenac sodium & secukinumab. Rheumatologist 2015;9(2):80.
Kaufman MB, Choy M. Updates from the ACR/ARHP Annual Meeting plus hydrocodone combination products & brodalumab. Rheumatologist 2015;9(1):76-77.
Kaufman MB. Pipeline, Drug Approvals & Study Updates - Hydrocodone bitartrate, secukinumab & varenicline. Rheumatologist 2014;8(12):90.
Kaufman MB. Atypical Fractures associated with Bisphophonates Plus FX006, odanacatib & more. Rheumatologist 2014;8(11):85.
Kaufman MB. Pipeline, Drug Approvals & Study Updates - decernotnib, subcutaneous methotrexate & more. Rheumatologist 2014;8(10):78.
Kaufman MB. Drugs in the Pipeline & Study Updates - atacicept & mavrilimumab. Rheumatologist 2014;8(9):69.
Kaufman MB. Drugs Studied for Use in RA & Weight Loss - Plus news from EULAR. Rheumatologist 2014;8(8):47.
Kaufman MB. Legislative Update on Biosimilars Plus safety warning on epidural corticosteroid injections. Rheumatologist 2014;8(6):47.
Kaufman MB. Trial and safety data - acetaminophen restrictions & more. Rheumatologist 2014;8(5):57.
Goldenberg L, Kaufman MB. Agent Orange, a Toxic Defoliant, and Its Association with Type 2 Diabetes. http://militarycme.com/clinical-articles/agent-orange,-a-toxic-defoliant,-and-its-association-with-type-2-diabetes-1148
Kaufman MB. Drug-Induced Pancreatitis - A Potentially Serious and Underreported Problem P&T 2013;38(6):349-351.
Kaufman MB. Business Development Institute Mobile Health Care Communications Summit. P&T 2013;38:228-230.
Kaufman MB. ACE Inhibitor-Related Angioedema - Are your patients at Risk? P&T 2013;38(3):170-172.
Kaufman MB. Meeting Highlights - 2012 American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition. P&T 2013;38(2):119-120.
Kaufman MB. Drug Watch: Anti-infectives and anti-fungal agents. Formulary 2013;48(1):32.
Kaufman MB , Choy M. Pregabalin and Simvastatin First Report of a Case of Rhabdomyolysis. P & T 2012;37:579-581,595.
Kaufman MB. Drug Watch: Pain. Formulary 2012;47(9):342.
Kaufman MB. From The Healthcare Communications 2012: Case Studies & Roundtables. Mobile health increases as physicians seek new ways to manage patients. Formulary 2012;47:161-162
Kaufman MB. From The Healthcare Communications 2012: Case Studies and Roundtables. Online communities for healthcare professionals can help improve communication, collaboration. Formulary 2012;47:161.
Kaufman MB. Mobile health service serves as catalyst to maternal, infant well-being.Formulary 2012;47:124.
Kaufman MB. Service encourages teens to text health-related questions.Formulary 2012;47:124.
Kaufman MB. Drug Watch: Breast Cancer. Formulary 2012;47(4):166.
Kaufman MB. Drug Updates and Medication Safety. Rheumatologist 2012;6(3):37-39.
Kaufman MB. Drug Watch: Hepatitis C virus (HCV) infection. Formulary 2012;47(3):127.
Kaufman MB. Social media helps health plans facilitate learning, promote credibility. Formulary 2011;46(12):509-510.
Kaufman MB. Drug Watch: Non-small-cell lung cancer. Formulary 2011;46(11):552.
Kaufman MB. Specialty drug approvals on the rise in 2011. From the Academy of Managed Care Pharmacy's 2011 Educational Conference, October 2011. Formulary 2011;46:547.
Kaufman MB. Mobile technology poised to redefine healthcare management. From the Academy of Managed Care Pharmacy's 2011 Educational Conference, October 2011. Formulary 2011;46:547-548.
Kaufman MB. Collaborative helps pharmacist navigate EHR arena. From the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase, April 2011. Formulary 2011;46:447.
Kaufman MB. Decision-makers urged to put personalized medicine into action From the Academy of Managed Care Pharmacy's 2011 Educational Conference, October 2011. Formulary 2011;46:502.
Kaufman MB. Specialty drug category grows with new approvals. From the Academy of Managed Care Pharmacy's 2011 Educational Conference, October 2011. Formulary 2011;46:502.
Kaufman MB. Creative contracting initiatives key for Pharma as competition in RA market increases. Formulary 2011;46:458.
Kaufman MB. Drug Watch: Agents for epilepsy and Parkinson's disease. Formulary 2011;46(11):505.
Kaufman MB. Drug Updates and Medication Safety. Rheumatologist 2011;5(11):45, 48, 49.
Kaufman MB. Growth of Mobile apps prompts FDA to seek input on proposed oversight approach.Formulary 2011;46:295-296.
Kaufman MB, Alberto NA, Bailey DS. Bleeding Associated with Anti-platelet agents and Warfarin in the Emergency Department. Arch Intern Med 2011;171(12):1126.
Jing S, Naliboff A, Kaufman MB, Choy M. Descriptive Analysis of Mail Interventions with Physicians and Patients to Improve Adherence with Antihypertensive and Antidiabetic Medications in a Mixed-Model Managed Care Organization of Commercial and Medicare Members. J Manag Care Pharm 2011;17(5):355-366.
Kaufman MB. Cancer, diabetes, cardiovascular agents fill pipeline. From the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase, April 2011. Formulary 2011;46:241.
Kaufman MB. Specialty drug approvals trend upwards; biobetters gain momentum. From the Academy of Managed Care Pharmacy's 23rd Annual Meeting and Showcase, April 2011. Formulary 2011;46:241.
Kaufman MB. Drug Watch: Psychiatric conditions. Formulary 2011;46:244.
Kaufman MB. Drug Watch: Major depressive disorder and generalized anxiety disorder. Formulary 2011;46:198.
Kaufman MB. Drug Updates and Medication Safety. Rheumatologist 2011;5(5):62, 64.
Kaufman MB. Rx Report. Dialysis & Transplantation 2011;40(4):179-180.
Kaufman MB. Intensive glycemic management leads to higher mortality in T2DM patients and New Recommendations for GDM. From the American Diabetes Association 58th Annual Advanced Postgraduate Course. Formulary 2011;46:149.
Kaufman MB. Drug Watch: Type 1 Diabetes Mellitus. Formulary 2011;46:152.
Kaufman MB. Rx Report. Dialysis & Transplantation 2011;40(2):89-90.
Kaufman MB. Use of HEOR data in formulary decision-making expected to increase. Formulary 2011;46:39.
Kaufman MB. Drug Watch: Cystic fibrosis. Formulary 2011;46:34 (February)
Kaufman MB, Alberto NA, Bailey DS. Comments - regarding bleeding associated with anti-platelet and warfarin therapy in the emergency department. Arch Intern Med. 2011 [Letter to the Editor], in press.
Perry L, Kaufman MB. Pipeline 2011. Drug Topics 2011;155:30-40.
Kaufman MB. Drug Watch: Osteoporosis and related bone disease agents. Formulary 2011;46:34 (January)
Kaufman MB. Greater vigilance needed for unapproved agents; reduce demand for these drugs by reporting adverse events. From the Academy of Managed Care Pharmacy's 2010 Educational Conference. Formulary 2010;45:359.
Kaufman MB. Management with specialty pharmaceuticals imminent for various conditions. From the Academy of Managed Care Pharmacy's 2010 Educational Conference. Formulary 2010;45:359-360.
Kaufman MB. The non-specialty pharmaceutical pipeline: What's on the horizon? From the Academy of Managed Care Pharmacy's 2010 Educational Conference. Formulary 2010;45:360.
Kaufman MB. Drug Updates and Medication Safety. Rheumatologist 2010;4(11):64-65.
Kaufman MB. Market Watch. The Hospitalist 2010;14(12):16.
Kaufman MB. Market Watch. The Hospitalist 2010;14(11).
Kaufman MB. Drug Watch: Multiple sclerosis agents. Formulary 2010;45:330 (November)
Kaufman MB. Drug Watch: Pulmonary disease agents. Formulary 2010;45:298 (September/October)
Kaufman MB. Drug Watch: Weight management agents. Formulary 2010;45:266 (August)
Kaufman MB. Drug Updates and Biologics for Pediatric Patients with Juvenile Idiopathic Arthritis. Rheumatologist 2010;4(7):36-37.
Kaufman MB. Drug Watch: Female and Male cancers. Formulary 2010;45:234 (July)
Kaufman MB. Specialty pharmacy management strategies continually updated. Published online June 11, 2010 as part of proceedings of the 22nd Annual AMCP Annual Meeting & Showcase, San Diego, CA (April 7-10, 2010) http://formularyjournal.modernmedicine.com/formulary/ArticleStandard/Article/detail/673350
Kaufman MB. Social networking helpful for patients, but may need to be vetted.
Published online June 11, 2010 as part of proceedings of the 22nd Annual AMCP Annual Meeting & Showcase, San Diego, CA (April 7-10, 2010) http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+News/Social-networking-helpful-for-patients-but-may-nee/ArticleStandard/Article/detail/673539?ref=25
Kaufman MB. Interventions can help curb adverse drug events. Published online June 11, 2010 as part of proceedings of the 22nd Annual AMCP Annual Meeting & Showcase, San Diego, CA (April 7-10, 2010) http://formularyjournal.modernmedicine.com/formulary/Modern+Medicine+News/Interventions-can-help-curb-adverse-drug-events/ArticleStandard/Article/detail/673537?contextCategoryId=44234
Kaufman MB. Market Watch. The Hospitalist 2010;14(6):14.
Kaufman MB. Stakeholder collaboration can aid REMS implementation. Published online May 1, 2010 as part of proceedings of the 22nd Annual AMCP Annual Meeting & Showcase, San Diego, CA (April 7-10, 2010)
http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/Stakeholder-collaboration-can-aid-REMS-implementat/ArticleStandard/Article/detail/670559
Kaufman MB. “At-Risk” generic launches can be unpredictable. Published online May 1, 2010 as part of proceedings of the 22nd Annual AMCP Annual Meeting & Showcase, San Diego, CA (April 7-10, 2010)
http://www.modernmedicine.com/modernmedicine/Modern+Medicine+Now/At-risk-generic-launches-can-be-unpredictable/ArticleStandard/Article/detail/670554
Kaufman MB. Drug Watch: Vaccines. Formulary 2010;45:202 (June)
Kaufman MB. Drug Updates. Rheumatologist 2010;4(5):26,33.
Kaufman MB. Market Watch. The Hospitalist 2010;14(5):14.
Kaufman MB. Drug Watch: Epilepsy/Seizure Disorders. Formulary 2010;45:170 (May)
Kaufman MB. Rx Report. Dialysis & Transplantation 2010;39(4):168.
Kaufman MB. Market Watch. The Hospitalist 2010;14(4):17.
Kaufman MB. Drug Updates. Rheumatologist 2010;4(3):31,39.
Kaufman MB. Drug Watch: Hepatitis C. Formulary 2010;45:138 (April)
Kaufman MB. Drug Watch: Diabetes. Formulary 2010;44:105 (March)
Kaufman MB. Drug Watch: Renal Diseases. Formulary 2010;45:72 (February)
Kaufman MB. Drug Watch: Anticoagulant and antiplatelet agents. Formulary 2010;45:32 (January)
Kaufman MB. Drug Watch: Selected Orphan Diseases. Formulary 2009;44(12):376.
Kaufman MB. Drug Updates – Information on New Approvals and medication safety: On the Horizon for Osteoporosis Management. Rheumatologist 2010;4(1):19-20.
Kaufman MB. Drug Updates – Information on New Approvals and medication safety: Vitamin D deficiency. Rheumatologist 2009;3(11):33-34.
Kaufman MB. Medication interventions get a boost from a powerful tool. Modern Medicine online Health Care IT. Available at: http://www.modernmedicine.com/modernmedicine/ModernMedicine+Now/Medication-interventions-get-a-boost-from-a-powerf/ArticleStandard/Article/detail/626170
Published September 14, 2009
Kaufman MB. Drug Updates and Bisphosphonate Safety. The Rheumatologist 2009;3(5):1,19,20.
Kaufman MB. Pharmacogenomics: Up Close and Personal – Medication reaction research could streamline drug trials, improve outcomes. The Hospitalist 2009;13(5):14.
Kaufman MB. Health help 4 u: Mobile telephone technologies come of age. Formulary 2009;44:154-155.
Kaufman MB. Drug Watch: Cystic Fibrosis. Formulary 2009;44(5):156.
Kaufman MB. Drug Watch: Complicated Infections. Formulary 2009;44(4):124.
Kaufman MB. Rx Report. Dialysis & Transplantation 2009;38(4):146.
Kaufman MB. To Crush or Not to Crush! The Hospitalist 2009;13(4):18.
Kaufman MB. Rx Report. Dialysis & Transplantation 2009;38(3):108.
Kaufman MB. Drug Updates. The Rheumatologist 2009;3(3):1,18,19.
Kaufman MB. C. Difficile Infection: Are We Doing Enough? Hospitalists can follow simple steps to avoid, manage this costly disease. The Hospitalist 2009;13(3):12,26.
Kaufman MB. QTc Interval Prolongation: Know your patient’s history, drug combinations before starting a new treatment. The Hospitalist 2009;13(2):7.
Kaufman MB. Rx Technology Report: Preventable medication errors: Look-alike/sound-alike mix-ups. Formulary 2009;44(2):59.
Kaufman MB. Drug Updates and Statin-Associated Myopathy. The Rheumatologist 2009;3(1):1,17,18.
Campbell M, Kaufman MB, Bendix J. Oral Oncology Drugs Navigating dispensing, billing, and reimbursement challenges is a daunting but not insurmountable task. Drug Topics , February 1, 2009.
Kaufman MB. Telepharmacy reaches out to the underserved Formulary Journal 2009 http://formularyjournal.modernmedicine.com/formulary/ArticleStandard/Article/detail/575698
Kaufman MB. Inhaled Insulin: Troubled Drug Rises from the Ashes. The Hospitalist 2009;13(1):10.
Kaufman MB. End of ’08 Drug Update. The Hospitalist 2008;12(12):18.
Kaufman MB. Rx Report. Dialysis & Transplantation 2008;37(12):506,513.
Kaufman MB. Drugs that Cause Movement Disorders. The Hospitalist 2008;12(10):17.
Kaufman MB. Rx Report. Dialysis & Transplantation 2008;37(10):411,412.
Kaufman MB. Serotonin Syndrome. The Hospitalist 2008;12(9):13.
Kaufman MB. Drug Watch: Agents in late stage development for Types 1 and 2 Diabetes Mellitus. Formulary 2008;43(9):344. Available at:
http://formularyjournal.modernmedicine.com/formulary/data/articlestandard//formulary/352008/546160/article.pdf
Navigating an Emerging Crossroad: Patient, Provider and Payer Considerations in Biologic Therapies for Immune-mediated Diseases (Medical Writer) September 2008. A four hour CME/CE monograph for physicians, pharmacists, nurse practitioners, physician’s assistants, nurses and case managers. Available at: http://primeinc.org/course/149.html
Kaufman MB. Drug Watch: Adult and juvenile rheumatoid arthritis. Formulary 2008;43(7):260. Available at: http://formularyjournal.modernmedicine.com/formulary/data/articlestandard//formulary/272008/526907/article.pdf
Kaufman MB. Rx Report. Dialysis & Transplantation 2008;37(6):214.
Kaufman MB. Be Aware of Agents associated with Drug-Induced Thrombocytopenia. The Hospitalist 2008;12(6):22.
Patient Encounters: Real Faces of Biologic Treatment in Related Disease Pathologies. Contributing Author for Live Symposia (slides and speaker notes) at the 18th Annual Case Management Society of America Annual Conference and Expo, Orlando, FL, June 18, 2008.
Kaufman MB. Rx Technology Report: Electronic medication management system available to improve medication adherence. Formulary 2008;43(6):223. Available at: http://formularyjournal.modernmedicine.com/
Kaufman MB. Rx Technology Report: High-tech solutions to reduce the incidence of hospital-acquired infections and antibiotic resistance. Formulary Journal online May 2008. Available at: http://formularyjournal.modernmedicine.com/
Kaufman MB. Protect the Platelets – Be Aware of agents associated with drug-induced thrombocytopenia. The Hospitalist 2008;12(5):22.
Capitalizing on Collaborative Strategies to Improve Care for Patients with Cystic Fibrosis. Contributing Author for Live Regional Symposia (slides and speaker notes), Spring 2008.
Navigating an Emerging Crossroad: Patient, Provider, and Payer Considerations in Biologic Therapies for Immune-mediated Diseases. Contributing Author for Live Symposia (slides and speaker notes). The 2008 Academy of Managed Care Pharmacy Annual Meeting, San Francisco, CA, April 18, 2008.
To Treat or Not to Treat? Debating the Utility of Antithrombotic Therapy in the Long-term Care Population. Contributing Author for Live Program (slides and speaker notes). American Medical Directors Association Meeting, March 6-9, 2008, San Diego, CA.
Kaufman MB. Vital VTE Intervention – Many hospitalized patients are at risk and need thromboprophylaxis. The Hospitalist 2008;12(4):15.
ASA Therapy and Beyond: Assessing the Current Role of Antiplatelet Therapy, Contributing Author for Live Program at the Society for Hospital Medicine Annual Meeting, April 4, 2008, San Diego, CA; and Contributing Author for online video presentation (slides and speaker notes) for continuing professional education available at: http://www.primeinc.org
Kaufman MB. Combat Adverse Events – Expanded FDA regulations bring new drug warnings. The Hospitalist 2008;12(3):13.
Kaufman MB. Rx Report. Dialysis & Transplantation 2008;37(3):106-107.
Kaufman MB. Liver Risks Abound – Acetaminophen leads other agents as cause of hepatotoxicity. The Hospitalist 2008;12(2):14.
Kaufman MB. Rx Report. Dialysis & Transplantation 2008;37(1):32-33.
Kaufman MB. Rx Technology Report: Bar coding helps improve patient safety. January 2008;43(1):30.
Kaufman MB. Manage Cancer Drugs – Renal function caveats. The Hospitalist 2008;12(1):14.
Kaufman MB. Avoid Pancreatitis Risk – More than 100 Medication have been implicated in this condition. The Hospitalist 2007;11(12):13-14.
Kaufman MB. Manage Cancer Drugs – How to handle the side effects of cell regulating medications. The Hospitalist 2007;11(11):13,16. Available at:
http://www.the-hospitalist.org/issues.asp
Kaufman MB. Rx Report. Dialysis & Transplantation 2007;36(11):616-617. Available at http://www3.interscience.wiley.co
Kaufman MB. Stress Ulcer Agents – Sucralfate, H2 receptor antagonists are valid classes. The Hospitalist 2007;11(10):13. Available at:
http://www.the-hospitalist.org/issues.asp
Kaufman MB. Rx Report.Dialysis and Transplantation 2007;36(10):554-555. Available at http://www3.interscience.wiley.co
Kaufman MB. Steroid Stress Dosing – How to negotiate the use of glucocorticoids. The Hospitalist 2007;11(9):12-13. Available at:
http://www.wiley.com/WileyCDA/Section/id-292144.html
Kaufman MB. Rx Report.Dialysis and Transplantation 2007;36(8):460-461. Available at http://www3.interscience.wiley.co
Kaufman MB. Rx Technology Report: How High-Tech Advances and Applications are Impacting Health-System and Managed-Care Pharmacy. Formulary Journal
Available at: http://www.formularyjournal.com
Web-based tools to improve case management.
Formulary 2007;42(6):408.
Automated IV and syringe preparation increases
safety, reduces errors. Formulary 2007;42(5):327.
E-prescribing offers a neat and safe alternative to
pad and pen. Formulary 2007;42(4):250.
RFID goes to work to help prevent errors,
tampering. Formulary 2007;42(3):197.
New diagnostic tool aids in pathogen
identification; kiosks in doctors' offices provide
generic drug samples. Formulary 2007;42(2):126.
Personal health records go portable; hospitals tap
into translation services by video.
Formulary 2007;42(1):55.
Kaufman MB. Rx Report: New Safety Warnings Released. Dialysis and Transplantation 2007;36(6):321. Available at http://www3.interscience.wiley.com
Hemoglobin Levels in CKD: What’s the Correct Level? Dialysis & Transplantation 2007;46(4): 236-237.
The Year in Review. Dialysis & Transplantation 2006;35(12):778-779.
Rx Report – The New Anemia Drugs. Dialysis & Transplantation 2006;35(9):588,590.
Plotting a Course to Manage Rheumatoid Arthritis. October 2007, Contributing Author for online video presentation (slides and speaker noted) for continuing professional education. Visit http://www.primeinc.org to access programs.
Plotting a Course to Manage Inflammatory Bowel Disease. October 2007, Contributing Author for online video presentation (slides and speaker noted) for continuing professional education. Visit http://www.primeinc.org to access programs.
Case Studies Optimizing Management of Depression and Anxiety. June 2007, contributing author for online video presentation (slides and speaker notes) for continuing professional education. Visit http://www.primeinc.org to access programs.
Interactive Discussion in the Current State of Diabetes Care January 2007: Contributing Author for online dynamic video presentation (slides and speaker notes) for continuing education.
Modernization Versus Limitation: Cross-Firing the Impact of the AHRQ Effective Health Care Program on Access to Biologic Therapies
Chao S, Fleming W, Solomon D, Urbano F. Journal of Managed Care Pharmacy Supplement 2007;13:S1-28. Contributing Author/Medical Writer Available at: http://www.amcp.org/data/jmcp/JanSuppl07.pdf
From Asthma Severity to Asthma Control – Identification of New Guideline Application.
Jones C, Endicott L, Kaufman MB. Supplement to Journal of Managed Care Pharmacy 2006;12:S1-S17. http://amcp.org/data/jmcp/Dec_suppl.pdf
The Hospital Pharmacy – Pain Killers: Agents to manage neuropathic pain in hospitalized patients. Kaufman MB. The Hospitalist 2006;10(9):11.
“Case-Based Approaches to Managing Future Formularies for Immune-Mediate Disease” June 2006: Contributing Author for online dynamic presentation for continuing education (slides and audio) Available at: http://www.primeinc.org/
“Optimizing Treatment Outcomes in Patients with Chemotherapy-Related Anemia” July 2006: Contributing Author for online dynamic video presentation for continuing education (slides and speaker notes). Information available through: http://www.primeinc.org/
“Breathing Easier: Using Evidence to Improve Outcomes for Patients with COPD” September 2006: Contributing Author for live one-hour presentations for continuing education (slides and speaker notes).
The Hospital Pharmacy -- Two New Insulin Products -- the scoop hospitalists need to know about Exubera and Levemir. Kaufman MB. The Hospitalist 2006;10:18-19.
Editorials available on at http://www.primeinc.org under Pharmacist "Case Studies"
March 2006: "To Sleep or Not to Sleep"
February 2006: "Generic Biotechnology Drug
Products"
January 2006: Disparities in Healthcare
December 2005: Revisiting Alcohol ‘Tis the Season
to be Jolly – But Don’t Overdo It
November 2005: : The Avian Influenza (H5N1) Primer
for Pharmacists
October 2005: Where Are We Going with HIV/AIDS?
September 2005: What’s New Since My Last Editorial
on Direct-to-Consumer Advertising (DTCA, June
2005)?
July 2005: Diabetes Treatments in 2005
June 2005: Impact of Direct-to-Consumer
Advertising
A Growth Hormone Conversion Program and Patient Outcomes at a not-for-profit HMO. Kaufman MB, Brodin KA, Sarafian A. Formulary 2006;41:82-90.
Effect of Prescriber Education on the Use of Medications Contraindicated in Older Patients in a Managed Medicare Population. Kaufman MB, Brodin KA, Sarafian A. Journal of Managed Care Pharmacy 2005;11:211-219.
A Treatment Conversion for Hepatitis C Virus (HCV). Kaufman MB, Magagna M, Brodin KA, Sarafian A.Supplement to Managed Healthcare Executive; April 2005;6-10.
Use of Proton-Pump Inhibitors at a Nonprofit, Mixed-Model Health Maintenance Organization. Kaufman MB, Alimonos K, Sarafian A. American Journal of Health-Systems Pharmacy 2004;61:2244-2246.
Can Mycophenolate Mofetil be used to Treat Lupus Nephritis, a Renal Manifestation of Systemic Lupus Erythematosus? Kaufman MB. US Pharmacist; October 2000:HS-22, HS-28, HS-30 & HS-31.
"Drug Watch" -- A Heads-Up on Pharmaceuticals in Late Stage Development. Formulary (January 1999 – present): Contributing Authors: Stultz T, Kaufman MB. Last page of journal each month at http://www.formularyjournal.com
A Review of Protease Inhibitor-induced Hyperglycemia. Kaufman MB, Simionatto C. Pharmacotherapy 1999;19:114-117.
Myoclonus from calcium channel blockers. Kaufman MB. US Pharm - Health Systems Edition 1996;August:82-6.
Feature Article: Acquired Immunodeficiency (AIDS) Treatment Review. Contributing Author/wrote feature Pharmacy and Therapeutics Newsletter of the Health Insurance Plan of Greater New York, Volume 7, Number 3 [Summer 1996 issue].
Bone and tissue changes following prostaglandin therapy in neonates. Kaufman MB, El-Chaar GM. Annals of Pharmacotherapy 1996;30:269-274,277.
Role of a pharmacist at resident physician's morning report in adverse drug reaction reporting. Kaufman MB. American Journal of Health-Systems Pharmacy 1995;52:2031.
Adverse effects associated with dexamethasone, lorazepam and granisetron [letter].Kaufman MB. Annals of Pharmacotherapy 1994;28:1306-1307.
Dystonic reaction associated with sumatriptan [letter]. Garcia G, Kaufman MB, Colucci RD. Annals of Pharmacotherapy 1994;28:1199.
Physician's liability for adverse drug reactions. Kaufman MB, Stoukides CA, Campbell NA. Southern Medical Journal 1994;87:780-784.
Galactopharmacopedia: Antihistamines in breast-feeding. Ghaeli P, Kaufman MB. J Hum Lact 1993;4:261-2.
Stability of undiluted trimethoprim-sulfamethoxazole for injection in plastic syringes. Kaufman MB, Scavone JM, Foley JJ. American Journal of Hospital Pharmacy 1992;49:2782-2783.
Corticosteroids in AIDS patients with Pneumocystis carinii pneumonia. Kaufman MB, DeMuria D.Annals of Pharmacotherapy 1992;26:932-933.
Acute renal failure associated with over-the-counter ibuprofen. Spierto RJ, Kaufman MB, Stoukides CA. Annals of Pharmacotherapy 1992;26:714.
Portuguese man-o-war envenomation. Kaufman MB. Pediatric Emergency Care 1992;8:27-28.
Angiotensin-converting enzyme inhibitors: class effects. Stoukides CA, Kaufman MB. The ADR Exchange 1991;4(4).
Ipecac intoxication. Kaufman MB. Clinical Toxicology Review 1990;13.